Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 335-340

  Balkham, S E ^a   Sargent, J M ^a   Elgie, A W ^a   Williamson, C J ^a   Taylor, C G ^a  

^a Pembury Hospital   (United Kingdom)

Author keywords

6TG; AML; Ara C; BAX; BCL 2; Drug resistance

Indexed keywords

BAX PROTEIN, HUMAN; CYTARABINE; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; BLOOD; BONE MARROW CELL; COMPARATIVE STUDY; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLAST CRISIS; BONE MARROW CELLS; CYTARABINE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOCYTIC, ACUTE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; THIOGUANINE;

EID: 0032616997     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_36     Document Type: Article

References (7)

1. Green D, Martin S. The killer and the executioner: How apoptosis controls malignancy. Current Opinion in Immunology, 1995, 7, 694-703.
2. Reed JC. BCL-2 and the regulation of programmed cell death. J Cell Biol, 1994, 124, 1-6.
3. Reed JC. BCL-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin, 1995, 9, 451-473.
4. Banker D, Groudine M. Measurement of spontaneous and therapeutic agent induced apoptosis with BCL-2 protein expression in acute myeloid leukaemia, Blood, 1997, 89, 243-255.
5. Brousset P, Benharroch D. Frequent expression of the cell death - inducing gene box in Rced-Sternberg cells in Hodgkin's Disease. Blood, 1996, 87, 2470-2478.
6. Pepper C, Bentley P. Regulation of clinical chemoresistance by BCL-2 and BAX oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol, 1996, 95, 513-517.
7. Pepper C, Hoy T. BCL-2/BAX ratios in chronic lymphoctic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer, 1997, 76, 935-938.